Oxford Laboratories Private Limited

Oxford Laboratories Private Limited, established on January 31, 2000, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2000PTC123927. As of the latest available data, Oxford Laboratories has an authorized capital of ₹2.50 crore and a paid-up capital of ₹1.50 crore. The company employs approximately 89 professionals across various functions.

Oxford Laboratories specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans multiple therapeutic categories, with a significant focus on antifungals, antibiotics, and antimalarial & antiparasitic agents. In the fiscal year ending March 31, 2024, Oxford Laboratories reported a substantial 18.9% increase in revenue and a 39.62% rise in profit, indicating robust financial health and operational efficiency.

Oxford Laboratories operates a state-of-the-art manufacturing plant located in Pardi, Gujarat. This facility is equipped to produce a diverse range of pharmaceutical formulations, including tablets, capsules, external preparations (creams, ointments, gels), liquid orals, injections (both small volume parenterals and large volume parenterals), nutraceuticals, and herbal Ayurvedic and cosmetic products. The plant adheres to stringent quality control measures and is accredited with WHO-GMP and ISO 9001:2015 certifications, underscoring its commitment to producing high-quality pharmaceutical products.

The leadership team at Oxford Laboratories comprises individuals with extensive experience in the pharmaceutical industry. The company's directors include Andrei Nikolaevich Medunitsyn and Satyajeet Sumant Khanolkar, both appointed on January 31, 2000. Their strategic vision and management acumen have been instrumental in steering the company towards significant growth and market expansion.

Oxford Laboratories has established a strong presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Gujarat is WHO-GMP certified, which is a prerequisite for exporting pharmaceutical products to these markets. While specific regulatory approvals for each country are not detailed in the available sources, the WHO-GMP certification indicates compliance with international manufacturing standards, facilitating market access in these regions.

Oxford Laboratories has strategically expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are promoted through its own marketing and sales setup in Russia, most of the CIS, and African countries, where they collaborate with marketing agencies to enhance market penetration. This approach has enabled Oxford Laboratories to establish a robust presence in these regions, catering to the growing demand for quality pharmaceutical products.

Oxford Laboratories demonstrates a diversified geographic strategy by operating in both regulated and emerging markets. This diversification mitigates concentration risk and positions the company to leverage growth opportunities across different regions. The company's strategic direction focuses on expanding its global footprint while maintaining high standards of quality and compliance with international regulations.

Specific details regarding Oxford Laboratories' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's WHO-GMP certification suggests adherence to international manufacturing standards, which is a critical component for FDA approvals. To obtain precise information on FDA approvals and inspections, direct communication with the company or the FDA would be necessary.

Oxford Laboratories' manufacturing facility in Gujarat holds WHO-GMP certification, indicating compliance with the World Health Organization's Good Manufacturing Practices. This certification is essential for exporting pharmaceutical products to various international markets, including the European Union. While specific EU GMP certificates or EDQM status are not detailed in the available sources, the WHO-GMP certification serves as a foundational requirement for market access in the EU.

Oxford Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facility in Gujarat is approved by the CDSCO, ensuring compliance with national standards for pharmaceutical manufacturing. Additionally, the company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export operations.

As of the latest available information, there are no publicly disclosed Form 483 observations, warning letters, or import alerts associated with Oxford Laboratories. The company's adherence to WHO-GMP and ISO 9001:2015 standards reflects its commitment to maintaining high-quality manufacturing practices and regulatory compliance.

Oxford Laboratories operates in a competitive pharmaceutical market, with key competitors in overlapping categories such as antifungals, antibiotics, and antimalarial & antiparasitic agents. While specific market share comparisons are not detailed in the available sources, the company's focus on quality manufacturing and strategic market expansion positions it favorably against competitors. The company's diversified product portfolio and adherence to international standards provide a competitive edge in both regulated and emerging markets.

Oxford Laboratories' commitment to quality is demonstrated through its WHO-GMP and ISO 9001:2015 certifications, ensuring adherence to international manufacturing standards. The company's diversified product portfolio, including tablets, capsules, external preparations, liquid orals, injections, nutraceuticals, and herbal Ayurvedic and cosmetic products, caters to a wide range of therapeutic needs. Additionally, Oxford Laboratories' strategic presence in both regulated and emerging markets enhances its global reach and market adaptability.

Oxford Laboratories' current strategic direction focuses on expanding its global footprint by entering both regulated and emerging markets. The company's commitment to quality manufacturing, as evidenced by its WHO-GMP and ISO 9001:2015 certifications, supports its growth objectives. Future outlooks suggest continued expansion through strategic partnerships and collaborations, enhancing its product offerings and market presence.

Oxford Laboratories has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $3.0 million USD and 114 shipments across four therapeutic categories. The company's portfolio concentration, with the top five products accounting for 100% of exports, indicates a focused approach to product development and market strategy. The company's adherence to WHO-GMP and ISO 9001:2015 standards further underscores its reliability as a supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• WHO-GMP Certification: Confirms adherence to the World Health Organization's Good Manufacturing Practices. Verification can be done by contacting the company directly or through the WHO's official channels.

• ISO 9001:2015 Certification: Indicates compliance with international quality management standards. Verification can be conducted by contacting the company or through the International Organization for Standardization's official website.

Importers should undertake the following steps to ensure a thorough evaluation of Oxford Laboratories:

• Verify Certifications: Confirm the validity of WHO-GMP and ISO 9001:2015 certifications through official channels.

• Assess Financial Health: Review the company's financial statements for the latest fiscal year to evaluate profitability and operational efficiency.

• Evaluate Product Portfolio: Analyze the company's product offerings to ensure alignment with market demands and quality standards.

• Check Regulatory Compliance: Ensure the company holds necessary manufacturing licenses and export No Objection Certificates (NOCs) from relevant authorities.

• Review Market Presence: Assess the company's presence in target markets to gauge reliability and market acceptance.

By conducting this due diligence, importers can make informed decisions regarding partnerships with Oxford Laboratories.